Smith+Nephew's TESSA Spatial Surgery System granted De Novo classification by the FDA sparking a generational leap in Sports Medicine for personalized planning and procedural innovation
Smith+Nephew introduces expanded enterprise ASC Solutions Strategy to support growth, performance and value-based care
Smith+Nephew announces first clinical cases with the next generation CORI?XT Handheld Robotics Platform across knee and shoulder arthroplasty
Smith+Nephew launch next generation LEAF Patient Monitoring System - an innovative pressure injury prevention platform delivering proven clinical impact
Smith+Nephew drives progress in chronic wound care with ALLEVYNCOMPLETE CARE Dressing and RENASYS EDGE tNPWT set to launch at EWMA 2026
New data for Smith+Nephew's CARTIHEAL? AGILI-C? Cartilage Repair Implant demonstrates superior pain relief and functional gains at 5-years
Smith+Nephew's REGENETEN? Bioinductive Implant shows post-operative recovery times halved, and high healing rates for partial-thickness rotator cuff tears1,*
Smith+Nephew's REGENETEN? Bioinductive Implant shows post-operative recovery times halved, and high healing rates for partial-thickness rotator cuff tears1,*
Smith+Nephew launches next-generation ALLEVYN COMPLETE CARE Foam Dressing - designed for high performance in wound management and pressure injury prevention
Smith+Nephew to showcase advanced Orthopaedic Handheld Robotics, Reconstruction and Trauma technologies during AAOS 2026
Smith+Nephew to feature leading rotator cuff repair portfolio including new Tendon Seam Repair System and REGENETEN? Bioinductive Implant at AAOS 2026
Smith+Nephew signs exclusive US distribution agreement with RMR Ortho for patented technology that provides a unique dynamic compression nitinol fixation option ) to our surgeons
Smith+Nephew completes acquisition of Integrity Orthopaedics; establishes unrivalled portfolio for shoulder repair
Heliostar Presents Q2 2026 Financial and Operating Results with Record Gold Production and Cash Balance
EraNova Announces Positive Preliminary Economic Assessment for the Adanac Molybdenum Project: After-Tax NPV of $714.4 Million and 23.5% IRR
